Immunohematological Data of B-CLL Patients
Patient . | Sex . | Stage . | WBC-151 . | Immunophenotype-150 . | sIg . | |||
---|---|---|---|---|---|---|---|---|
CD3 . | CD14 . | CD5/CD19-152 . | CD23 . | |||||
1 | M | 0 | 108 | 3 | ND | 81 | 70 | Mλ |
2 | M | I | 22 | 12 | 0 | 61 | 61 | Mλ |
3 | M | 0 | 16 | 20 | 3 | 74 | 36 | Dκ |
4 | M | 0 | 66 | 5 | 1 | 95 | 90 | Mλ |
5 | F | 0 | 13 | 22 | 0 | 40 | 48 | Mλ |
6 | M | II | 34 | 12 | 0 | 83 | 75 | Dκ |
7 | M | I | 53 | 12 | 0 | 52 | 87 | Mλ |
8 | F | I | 73 | 11 | 4 | 45 | ND | Dκ |
9 | M | 0 | 31 | 8 | 10 | 88 | 84 | Mλ |
10 | F | I | 14 | 8 | 14 | 90 | 62 | Mλ |
11 | M | 0 | 44 | 6 | 3 | 1 | 84 | Mκ |
12 | F | I | 141 | 6 | 2 | 89 | 17 | Dλ |
13 | M | II | 83 | 56 | 4 | 37 | 40 | Mλ |
14 | M | III | 143 | 4 | 0 | 92 | 92 | Mκ |
15 | M | II | 41 | 10 | 0 | 81 | 64 | Mλ |
16 | F | III | 96 | 4 | 6 | 82 | 94 | Dκ |
17 | F | 0 | 16 | 31 | 0 | 53 | 66 | Dκ |
18 | M | 0 | 38 | 10 | 0 | 38 | 75 | Dκ |
19 | M | 0 | 76 | 2 | 1 | 92 | 85 | Mλ |
20 | F | 0 | 26 | 6 | ND | 74 | 47 | Dκ |
Patient . | Sex . | Stage . | WBC-151 . | Immunophenotype-150 . | sIg . | |||
---|---|---|---|---|---|---|---|---|
CD3 . | CD14 . | CD5/CD19-152 . | CD23 . | |||||
1 | M | 0 | 108 | 3 | ND | 81 | 70 | Mλ |
2 | M | I | 22 | 12 | 0 | 61 | 61 | Mλ |
3 | M | 0 | 16 | 20 | 3 | 74 | 36 | Dκ |
4 | M | 0 | 66 | 5 | 1 | 95 | 90 | Mλ |
5 | F | 0 | 13 | 22 | 0 | 40 | 48 | Mλ |
6 | M | II | 34 | 12 | 0 | 83 | 75 | Dκ |
7 | M | I | 53 | 12 | 0 | 52 | 87 | Mλ |
8 | F | I | 73 | 11 | 4 | 45 | ND | Dκ |
9 | M | 0 | 31 | 8 | 10 | 88 | 84 | Mλ |
10 | F | I | 14 | 8 | 14 | 90 | 62 | Mλ |
11 | M | 0 | 44 | 6 | 3 | 1 | 84 | Mκ |
12 | F | I | 141 | 6 | 2 | 89 | 17 | Dλ |
13 | M | II | 83 | 56 | 4 | 37 | 40 | Mλ |
14 | M | III | 143 | 4 | 0 | 92 | 92 | Mκ |
15 | M | II | 41 | 10 | 0 | 81 | 64 | Mλ |
16 | F | III | 96 | 4 | 6 | 82 | 94 | Dκ |
17 | F | 0 | 16 | 31 | 0 | 53 | 66 | Dκ |
18 | M | 0 | 38 | 10 | 0 | 38 | 75 | Dκ |
19 | M | 0 | 76 | 2 | 1 | 92 | 85 | Mλ |
20 | F | 0 | 26 | 6 | ND | 74 | 47 | Dκ |